Astellas Pharma Inc
TSE:4503
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 257
2 007
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
Astellas Pharma Inc
stock under the Base Case scenario is
hidden
JPY.
Compared to the current market price of 2 007 JPY,
Astellas Pharma Inc
is
hidden
.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
Astellas Pharma Inc
Astellas Pharma Inc looks overvalued. Yet it might still be cheap by its own standards. Some stocks live permanently above intrinsic value; Historical Valuation reveals whether Astellas Pharma Inc usually does or if today's premium is unusual.
Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Astellas Pharma Inc.
| US |
|
Eli Lilly and Co
NYSE:LLY
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Revenue & Expenses Breakdown
Astellas Pharma Inc
Balance Sheet Decomposition
Astellas Pharma Inc
| Current Assets | 1.4T |
| Cash & Short-Term Investments | 295.7B |
| Receivables | 716.4B |
| Other Current Assets | 356.7B |
| Non-Current Assets | 2.1T |
| Long-Term Investments | 130.3B |
| PP&E | 334.2B |
| Intangibles | 1.5T |
| Other Non-Current Assets | 162.9B |
| Current Liabilities | 1.3T |
| Accounts Payable | 168.7B |
| Other Current Liabilities | 1.2T |
| Non-Current Liabilities | 512.4B |
| Long-Term Debt | 320B |
| Other Non-Current Liabilities | 192.4B |
Free Cash Flow Analysis
Astellas Pharma Inc
| JPY | |
| Free Cash Flow | JPY |
Earnings Waterfall
Astellas Pharma Inc
|
Revenue
|
2T
JPY
|
|
Cost of Revenue
|
-375.7B
JPY
|
|
Gross Profit
|
1.6T
JPY
|
|
Operating Expenses
|
-1.5T
JPY
|
|
Operating Income
|
145.8B
JPY
|
|
Other Expenses
|
-21B
JPY
|
|
Net Income
|
124.9B
JPY
|
Profitability Score
Profitability Due Diligence
Astellas Pharma Inc's profitability score is hidden . The higher the profitability score, the more profitable the company is.
Score
Astellas Pharma Inc's profitability score is hidden . The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Astellas Pharma Inc's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Score
Astellas Pharma Inc's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Astellas Pharma Inc
According to Wall Street analysts, the average 1-year price target for
Astellas Pharma Inc
is 1 879.15 JPY
with a low forecast of 1 313 JPY and a high forecast of 2 520 JPY.
Dividends
Current shareholder yield for
Astellas Pharma Inc is
hidden
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
Astellas Pharma Inc
stock under the Base Case scenario is
hidden
JPY.
Compared to the current market price of 2 007 JPY,
Astellas Pharma Inc
is
hidden
.